Patricia Severns

发表

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound

S. Treon, Z. Hunter, J. Castillo, 2018, American journal of hematology.

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia

S. Treon, J. Castillo, K. Meid, 2018, Haematologica.

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2018, Clinical Cancer Research.

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

N. Gray, Jinhua Wang, S. Treon, 2018, Blood.

BTK drives ibrutinib resistance via ERK1/2, and protects BTK MYD88 mutated cells by a paracrine mechanism

Amanda, N. Gray, Jinhua Wang, 2018 .

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

S. Treon, N. Raje, Z. Hunter, 2017 .

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

R. Advani, J. Laubach, S. Treon, 2017 .

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.